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Xiangdong Wang1,2* and Peter A Ward3The word “biomarker” describes a traceable and charac-
terized substance that is an indicator of biological
morphology, processes and function. Disease biomarkers
are used to diagnose various phases of diseases, monitor
severities of diseases and responses to therapies, and are
predictors of prognosis of patients and likely responses
to therapy. One of criteria to evaluate the value of dis-
ease biomarkers is the disease-associated specificity, sen-
sitivity, traceability, stability, repeatability and reliability.
Increasing numbers of biomarkers are being discovered
and identified from preclinical research, but only a few
have been found to be useful clinically. The Journal of
Translational Medicine opens a new Section of Disease
Biomarkers to bridge identification and validation of
gene or protein-based biomarkers, network biomarkers,
dynamic network biomarkers in human diseases, patient
phenotypes, and clinical applications. The Section
intends to accelerate the discovery and development of
human disease-specific biomarkers for the early diagno-
sis, and monitoring, evaluation of diseases and predic-
tions of responses to therapy. The Section will be an
important and critical platform to underscore the signifi-
cance and value of Disease Biomarkers and promote
innovation and development of disease-specific biomar-
kers by integrating multidisciplinary aspects of science.
The following are aspects of the planned biomarker
studies:
a) Benefitting drug development: Disease biomarkers
can play critical roles not only in clinical applications
but also in drug discovery and development as
related to drug efficacy or toxicity, allowing selection
of “the right drugs and the right patients” [1]. For* Correspondence: xiangdong.wang@clintransmed.org
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distribution, and reproduction in any medium, pexample, more than 90% of new anti-cancer drugs in
clinical trials have failed marketing approval, often
due to poor efficacies and efficiencies, high toxicities,
drug resistance and unexpected safety issues. The
lack of disease-specific biomarkers is a major
problem, often making it difficult to predict drug
efficacy. The Section of Disease Biomarkers will
accelerate the use of biomarker identification and
validation for determining drug effects, target
specificities and binding, dynamic metabolism and
pharmacological kinetics, toxicity profiles, and side-
effects. In addition, Disease Biomarkers will
emphasize the importance of molecular and cellular
responses to drugs under pathophysiological
conditions, creating a new concept of “the right
biomarker, the right drug and the right patient”. This
will benefit our understanding of molecular
mechanisms of interactions between biomarkers,
drugs and diseases. Optimal biomarkers should allow
monitoring drug efficacy and safety and individual
responses to specific treatments. Patients evaluated
and treated at the early stage of disease may enhance
business decisions related to drug development,
facilitating regulatory approval for new therapies [2].
Quantification and safety of biomarkers are necessary
for final decisions related to new drug development
and applications.
b) Integration of multidisciplinary sciences:
Identification, validation, development and marketing
of disease-specific biomarkers are integrated
processes in molecular biology, involving new
biotechnologies, clinical sciences, regulatory policies,
and clinical applications. “Omic” science and
technology play important roles in the identification
and discovery of biomarkers. The Omic scope
includes genomics, proteomics, metabolomics,
pharmacogenomics, transcriptomics, and other high-
throughput methodologies. Selected biomarkerl Ltd. This is an Open Access article distributed under the terms of the
ativecommons.org/licenses/by/2.0), which permits unrestricted use,
rovided the original work is properly cited.
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computational biology, high-throughput image
analysis, molecular genetics, specimens from human
tissue banks, mathematical medicine and biology,
protein expression and profiling, and systems
biology. Clinical bioinformatics have been suggested
as a new way to combine clinical measurements and
signs with human tissue-generated bioinformatics,
helping to understand the role of selected biomarker
candidates in clinical settings, disease development
and progression, and therapeutic strategies, mapping
relationships of drug and biomarker candidates with
clinical examinations, pathology data, biochemical
analysis, and imaging and therapies [3]. An example
of targeted biomarker validation has been the study
drug localization, is tissues, using imaging data of
targeted tumor regions in various lung
compartments. Another example is selectivity and
precision of proteomic analyses in patients with
chronic lung diseases and cancer [4]. Panels of
disease-specific protein biomarkers that define the
disease stage were selected in chronic obstructive
pulmonary disease. By targeted proteomic analysis, a
digital evaluation score system was developed for
assessing severity of disease, useful, bioinformatics
information, and lung function [5,6]. A number of
new integrated scientific areas have been created
during the identification and development of disease-
specific biomarkers. Genomic medicine was
proposed to bring biomarkers into the mainstream of
clinical practice and improve therapies and quality of
patient life, although such strategies are in the very
early stages. Systems clinical medicine has been
defined as one of new strategic areas for
development of disease biomarkers, involving
integration of systems biology, clinical phenotypes,
high-throughout technologies, bioinformatics and
computational science in order to improve diagnosis,
prognosis and therapies of diseases [7]. Next
generation sequencing for genomic analysis of
individual genomes has been used for single
nucleotide polymorphism discovery and estimates of
allele frequency, gene ontology analysis of the target
genes, analysis of the microRNAs expression,
sequencing platforms for mRNA biomarker analysis,
genome-wide analysis, and the exploration of the
proteome, all of which should lead to the
identification of useful protein biomarkers.
c) Significance of molecular imaging in validation of
biomarkers: It has been suggested that selected
biomarker candidates need to be validated in human
tissues, (e.g. measuring the expression of targeted
mRNA and proteins in pathological tissues of
patients) as well as correlating the over-expression oftargeted candidates with dysfunction of organs or
tissues. Tissue microarray analysis is a powerful tool
for validation of biomarker candidates, especially
with an algorithm-tissue array co-occurrence matrix
analysis for quantifying cellular phenotypes based on
textural regularity by local inter-pixel configurations
[8]. In addition, matrix-assisted laser desorption/
ionization mass spectrometry imaging is used for
spatial distribution and relative abundance of
biomolecules directly in tissues in order to improve
the quality of molecular images and differentiate
tissue regions that cannot be morphologically
defined. It has been suggested that such imaging may
be beneficial for disease diagnosis and prognosis,
biomarker discovery and drug therapy, even though
there are still many barriers. As an example, clinical
phenotypes and severities of chronic obstructive
pulmonary disease were measured by the parametric
response map, a voxel-wise image analysis technique
of whole-lung using computed tomography that
results in more accurate diagnosis of individual
patients, together with integration of clinical
information [9]. Numerous imaging technologies
have been applied for biomarker validation and
development, including near infrared imaging,
neuronuclear imaging, whole-body diffusion
magnetic resonance imaging, specific biomarker
detection on the cell surface in real time, positron
emission tomography, molecular contrast-enhanced
ultrasound imaging, and acceptor fluorescence
anisotropy that measures variations in hetero-
fluorescence resonance energy transfer deriving from
protein-protein interactions.
d)Network biomarkers and dynamic network
biomarkers: Multiple biomarkers were found to
improve the prediction of death from cardiovascular
causes during a more than 10 year follow-up of
patients, suggesting that simultaneous presence of
biomarkers in cardiovascular disease as well as
presence of established risk factors substantially
improves the risk stratification for death from
cardiovascular disease in elderly men [10]. Network
biomarkers and dynamic network biomarkers
represent new types of biomarkers with protein-
protein or gene-gene interactions that can be
monitored and evaluated at different stages and time
points during development of disease [11]. The
amount of high-throughput genomic and proteomic
data from patients has been rapidly increasing and is
expected to correlate with clinical phenotypes,
disease severities, therapeutic responses, and
prognosis. Gene regulatory networks or protein
interaction networks may describe functions for the
panel of relevant network biomarkers. Dynamic
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various stages in diseases and seem to have disease
specificity. Disease biomarkers need to be validated
by integration with clinical informatics, which
translates clinical descriptive information on signs,
symptoms, biochemical analyses, imaging and
therapies into digital data [5,6]. Clinical
bioinformatics may be helpful in discovering disease-
specific, stage-specific, severity-specific and therapy-
predictive biomarkers.
e) Challenges in development: As one of major
technologies for biomarker identification and
discovery, genomics and proteomics as well as
sequencing still face a large number of challenges,
(e.g., analysis of the individual’s genome in the
context of extensive population-based data,
phenotypic significance and specificity, duration and
severity, of disease, genomic or proteomic variation,
combinations of genomic, expression-based,
metabolomic, and proteomic data, and the value of
disease biomarkers for making clinical decision).
Some tissue microarrays have been questioned due
to study sizes, reduced throughput, variability, and
expenses related to the observations. A recent study
combined genome-wide association with forced
expiratory volume in 1 second and the ratio of
forced expiratory volume in 1 second to forced vital
capacity, identified 16 new genomic regions showing
association with pulmonary function [12]. Those
biomarkers were selected from 48,201 individuals of
European ancestry, with follow up of top associations
in an additional 46,411 individuals. However, there is
further need to better understand the biomarkers
associated with molecular mechanisms involving
pulmonary function and validate selected targets in
order to reduce lung dysfunction.Conclusions
The Section of Disease Biomarkers is expected to accel-
erate the process from identification to validation, re-
search to development, resulting in improved design of
clinical trials. There should also be positive impacts on
governmental approval, and clinical applications to pol-
icy and regulation, and relevance to “personalized” medi-
cine and to public health. The Section will publish
articles related to development of advanced biotechnolo-
gies for biomarker discovery, the biomarkers associated
with the early detection of diseases, and monitoring of
disease severity and duration as well as patient responses
to therapies, predictions of patient outcomes and life
qualities, the clinical trial and evaluation of biomarkers,
and regulation and ethics of disease biomarkers.Author details
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